Urokinase-type plasminogen activator receptor: a beacon of malignancy?

Abstract

Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.

EDRN PI Authors
Medline Author List
  • Clauss A
  • Drapkin R
  • Skates S
PubMed ID
Appears In
Clin Cancer Res, 2008 Sep, volume 14 (issue 18)